JosÃ© Alexandre Ferreira

List of Publications by Year
in descending order

58 papers	3,126 citations	201674 27 h-index	161849 54 g-index
60 all docs	60 docs citations	60 times ranked	5379 citing authors

#	Article	IF	Citations
1	Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nature Cell Biology, 2018, 20, 332-343.	10.3	1,101
2	Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks. Frontiers in Oncology, 2019, 9, 380.	2.8	201
3	Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resistance Updates, 2016, 24, 34-54.	14.4	124
4	Probing the O-Glycoproteome of Gastric Cancer Cell Lines for Biomarker Discovery*. Molecular and Cellular Proteomics, 2015, 14, 1616-1629.	3.8	91
5	Sialyl Tnâ€expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Molecular Oncology, 2014, 8, 753-765.	4.6	88
6	New trends in guided nanotherapies for digestive cancers: A systematic review. Journal of Controlled Release, 2015, 209, 288-307.	9.9	87
7	Overexpression of tumourâ€associated carbohydrate antigen sialylâ€Tn in advanced bladder tumours. Molecular Oncology, 2013, 7, 719-731.	4.6	79
8	Synthesis and Optimization of Lectin Functionalized Nanoprobes for the Selective Recovery of Glycoproteins from Human Body Fluids. Analytical Chemistry, 2011, 83, 7035-7043.	6.5	72
9	the predominance of M2 polarized macrophages in the stroma of low hypoxic bladder tumors is associated with BCG immunotherapy failure11The first author has a PhD Grant (SFRH/BD/43399/2008) and J.A.F. has a Postdoctoral Grant (SFRH/BPD/66288/2009) from FCTâ€"FundaÃ§Ã£o para a CiÃªncia e Tecnologia, co-financed by European Social Fund (ESF) under Human Potential Operation Programme (POPH) from National Strategic Reference Framework (NSRF). We thank to LPCC, Portuguese League Against Cancer (NRNorte) for their supp. Urologic Oncology: Seminars and Original Investigations, 29.	1.6	66
10	Glycoproteomic Analysis of Serum from Patients with Gastric Precancerous Lesions. Journal of Proteome Research, 2013, 12, 1454-1466.	3.7	65
11	Protein glycosylation in gastric and colorectal cancers: Toward cancer detection and targeted therapeutics. Cancer Letters, 2017, 387, 32-45.	7.2	65
12	Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics. PLoS ONE, 2015, 10, e0141253.	2.5	62
13	Structural Ripening-Related Changes of the Arabinan-Rich Pectic Polysaccharides from Olive Pulp Cell Walls. Journal of Agricultural and Food Chemistry, 2007, 55, 7124-7130.	5.2	61
14	Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes proteinO-glycosylation extension. Oncotarget, 2016, 7, 63138-63157.	1.8	58
15	Targeted Oâ€glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advancedâ€stage bladder tumours. Molecular Oncology, 2017, 11, 895-912.	4.6	50
16	Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1795-1808.	2.4	49
17	CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications. Clinical Proteomics, 2018, 15, 22.	2.1	42
18	The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-GuÃ©rin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. BJU International, 2015, 116, 753-763.	2.5	41

#	Article	IF	Citations
19	Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 675.e1-675.e8.	1.6	39
20	Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. Theranostics, 2020, 10, 4903-4928.	10.0	39
21	Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?. Oncotarget, 2017, 8, 91734-91764.	1.8	37
22	Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy. British Journal of Cancer, 2013, 109, 2106-2114.	6.4	36
23	Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications. New Biotechnology, 2019, 49, 77-87.	4.4	31
24	P53 and Cancer-Associated Sialylated Glycans Are Surrogate Markers of Cancerization of the Bladder Associated with Schistosoma haematobium Infection. PLoS Neglected Tropical Diseases, 2014, 8, e3329.	3.0	30
25	Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. International Journal of Pharmaceutics, 2019, 570, 118646.	5.2	30
26	Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer. Talanta, 2018, 184, 347-355.	5.5	29
27	Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2â€“6 sialic acids. Scientific Reports, 2018, 8, 12196.	3.3	29
28	Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review. Journal of Controlled Release, 2015, 214, 40-61.	9.9	28
29	Dimeric calcium complexes of arabinan-rich pectic polysaccharides from Olea europaea L. cell walls. Carbohydrate Polymers, 2006, 65, 535-543.	10.2	27
30	ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab. Oncogene, 2021, 40, 3719-3733.	5.9	27
31	Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study. Anticancer Research, 2014, 34, 735-44.	1.1	26
32	A functional glycoproteomics approach identifies CD13 as a novel E-selectin ligand in breast cancer. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2069-2080.	2.4	23
33	Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells. Cancers, 2020, 12, 861.	3.7	20
34	Reference Genes for Addressing Gene Expression of Bladder Cancer Cell Models under Hypoxia: A Step Towards Transcriptomic Studies. PLoS ONE, 2016, 11, e0166120.	2.5	18
35	Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 221-236.	1.6	17
36	Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 191.	8.6	17

#	Article	IF	Citations
37	MHC Class I Stability is Modulated by Cell Surface Sialylation in Human Dendritic Cells. Pharmaceutics, 2020, 12, 249.	4.5	16
38	FASL polymorphism is associated with response to bacillus Calmette-GuÃ©rin immunotherapy in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 44.e1-44.e7.	1.6	14
39	In silico approaches for unveiling novel glycobiomarkers in cancer. Journal of Proteomics, 2018, 171, 95-106.	2.4	14
40	Helicobacter pylori lipopolysaccharide structural domains and their recognition by immune proteins revealed with carbohydrate microarrays. Carbohydrate Polymers, 2021, 253, 117350.	10.2	14
41	Target Scoreâ€"A Proteomics Data Selection Tool Applied to Esophageal Cancer Identifies GLUT1-Sialyl Tn Glycoforms as Biomarkers of Cancer Aggressiveness. International Journal of Molecular Sciences, 2021, 22, 1664.	4.1	14
42	Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. Genomics, Proteomics and Bioinformatics, 2021, 19, 25-43.	6.9	14
43	Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics, 2022, 12, 3150-3177.	10.0	14
44	Bioaccumulation of Amyloseâ€Like Glycans by Helicobacter pylori. Helicobacter, 2009, 14, 559-570.	3.5	12
45	Differentiation of isomeric Lewis blood groups by positive ion electrospray tandem mass spectrometry. Analytical Biochemistry, 2010, 397, 186-196.	2.4	12
46	Challenging the limits of detection of sialylated <scp>T</scp>homsenâ€“<scp>F</scp>riedenreich antigens by inâ€gel deglycosylation and nanoâ€<scp>LC</scp>â€<scp>MALDI</scp>â€<scp>TOF</scp>â€<scp>MS</scp>. Electrophoresis, 2013, 34, 2337-2341.	2.4	12
47	Identification of cell-surface mannans in a virulent Helicobacter pylori strain. Carbohydrate Research, 2010, 345, 830-838.	2.3	11
48	Efficiency of purification methods on the recovery of exopolysaccharides from fermentation media. Carbohydrate Polymers, 2020, 231, 115703.	10.2	10
49	Aldobiouronic acid domains in Helicobacter pylori. Carbohydrate Research, 2011, 346, 638-643.	2.3	8
50	Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies. Frontiers in Oncology, 2020, 10, 1774.	2.8	8
51	Glycoprotein Enrichment Method Using a Selective Magnetic Nano-Probe Platform (MNP) Functionalized with Lectins. Methods in Molecular Biology, 2015, 1243, 83-100.	0.9	8
52	Process for detecting Helicobacter pylori using aliphatic amides. Analytical and Bioanalytical Chemistry, 2011, 401, 1889-1898.	3.7	7
53	Humoral response against sialylâ€Le^a glycosylated protein species in esophageal cancer: Insights for immunoproteomic studies. Electrophoresis, 2015, 36, 2902-2907.	2.4	6
54	Single-pot enzymatic synthesis of cancer-associated MUC16 O-glycopeptide libraries and multivalent protein glycoconjugates: a step towards cancer glycovaccines. New Journal of Chemistry, 2021, 45, 9197-9211.	2.8	6

#	Article	IF	Citations
55	Helicobacter pylori cell-surface glycans structural features: role in gastric colonization, pathogenesis, and carbohydrate-based vaccines. Carbohydrate Chemistry, 2011, , 160-193.	0.3	6
56	A roadmap for translational cancer glycoimmunology at single cell resolution. Journal of Experimental and Clinical Cancer Research, 2022, 41, 143.	8.6	5
57	The Tumour Microenvironment and Circulating Tumour Cells: A Partnership Driving Metastasis and Glycan-Based Opportunities for Cancer Control. Advances in Experimental Medicine and Biology, 2021, 1329, 1-33.	1.6	2
58	Comparison of Two Processes for Isolation of Exopolysaccharide Produced byLactobacillus acidophilus. , 0, , 280-285.		1